Mustang Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

License, Clinical Trial and Sponsored Research Agreements (Tables)

License, Clinical Trial and Sponsored Research Agreements (Tables)

9 Months Ended

Sep. 30, 2019

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Schedule of license, clinical trial and sponsored research agreements

For the three and nine months ended September 30, 2019 and 2018, the Company recorded the following expense in research and development for licenses acquired:


	For the three months ended				For the nine months ended
	September 30,				September 30,
($ in thousands)	2019		2018		2019		2018
City of Hope
CD123	$	—	$	—	$	250	$	—
CS1		—		—		200		—
Manufacturing		—		—		—		75
PSCA		200		—		200		—
Calimmune		200		—		200		—
UCLA		300		—		300		—
St. Jude - XSCID		—		1,000		—		1,000
Nationwide Children's Hospital - C134		—		—		200		—
Total	$	700	$	1,000	$	1,350	$	1,075

Sponsored Research And Clinical Trial Agreements [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Schedule of license, clinical trial and sponsored research agreements

For the three and nine months ended September 30, 2019 and 2018, the Company recorded the following expense in research and development for sponsored research and clinical trial agreements:


	For the three months ended September 30,				For the nine months ended September 30,
	2019		2018		2019		2018
($ in thousands)
City of Hope	$	500	$	500	$	1,500	$	1,500
City of Hope - CD123		269		123		1,028		387
City of Hope - IL13Rα2		244		346		811		849
City of Hope - Manufacturing		114		114		343		344
Fred Hutch - CD20		49		255		690		938
BIDMC - CRISPR		—		69		69		69
Total	$	1,176	$	1,407	$	4,441	$	4,087